[ad_1]
MIRAMAR, FL, Dec. 16, 2021 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTC: GNTW), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has launched a new investor relations section of its web site. The company’s updated investor relations site features easy access to key investor information, such as News and Media, Detailed Price Quote, Filings, and Price History, and can be found at www.stemtech.com.
“Our enhanced investor relations web site reflects our commitment to offer the investment community user-friendly, efficient access to important updates about the Company,” said Charles S. Arnold, Chairman and CEO of Stemtech. “As a company, we believe in transparency and we hope that investors view our web site as a primary gateway to stay abreast of Company developments and disclosure filings. We plan to improve additional components of our web site and our online presence in the near future, and will keep Stemtech stakeholders updated as we implement new functionality and design upgrades.”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena,
908-675-0581,
fpena@stemtech.com
[ad_2]
Source link
